For example, intratumoral delivery of CCL21-modified DCs increased intratumoral CD8+ T cell frequencies, and upregulated PD-L1 expression and systemic immune activation in NSCLC, providing a strong rationale for combining CCL21-based vaccines with PD-1 blockade [87]. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.